Rallybio Statistics
Total Valuation
Rallybio has a market cap or net worth of $73.37 million. The enterprise value is -$20.47 million.
Market Cap | 73.37M |
Enterprise Value | -20.47M |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Rallybio has 41.45 million shares outstanding. The number of shares has increased by 1.30% in one year.
Shares Outstanding | 41.45M |
Shares Change (YoY) | +1.30% |
Shares Change (QoQ) | +0.32% |
Owned by Insiders (%) | 4.06% |
Owned by Institutions (%) | 75.78% |
Float | 23.20M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.82 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.77, with a Debt / Equity ratio of 0.00.
Current Ratio | 9.77 |
Quick Ratio | n/a |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.60% and return on invested capital (ROIC) is -89.77%.
Return on Equity (ROE) | -66.60% |
Return on Assets (ROA) | -61.50% |
Return on Capital (ROIC) | -89.77% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.54M |
Employee Count | 30 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.62% in the last 52 weeks. The beta is -1.63, so Rallybio's price volatility has been lower than the market average.
Beta (1Y) | -1.63 |
52-Week Price Change | -68.62% |
50-Day Moving Average | 1.77 |
200-Day Moving Average | 2.88 |
Relative Strength Index (RSI) | 47.68 |
Average Volume (30 Days) | 1,601,516 |
Short Selling Information
The latest short interest is 1.96 million, so 4.72% of the outstanding shares have been sold short.
Short Interest | 1.96M |
Short Previous Month | 2.96M |
Short % of Shares Out | 4.72% |
Short % of Float | 8.44% |
Short Ratio (days to cover) | 0.47 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -80.35M |
Pretax Income | -76.28M |
Net Income | -76.28M |
EBITDA | -76.13M |
EBIT | -76.28M |
Earnings Per Share (EPS) | -$1.87 |
Balance Sheet
The company has $94.18 million in cash and $339,000 in debt, giving a net cash position of $93.84 million or $2.26 per share.
Cash & Cash Equivalents | 94.18M |
Total Debt | 339,000 |
Net Cash | 93.84M |
Net Cash Per Share | $2.26 |
Equity / Book Value | 89.16M |
Book Value Per Share | 2.15 |
Working Capital | 88.46M |
Cash Flow
In the last 12 months, operating cash flow was -$56.96 million and capital expenditures -$12,000, giving a free cash flow of -$56.97 million.
Operating Cash Flow | -56.96M |
Capital Expenditures | -12,000 |
Free Cash Flow | -56.97M |
FCF Per Share | -$1.40 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Rallybio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.30% |
Shareholder Yield | -1.30% |
Earnings Yield | -103.97% |
FCF Yield | -77.65% |
Analyst Forecast
The average price target for Rallybio is $8.90, which is 402.83% higher than the current price. The consensus rating is "Buy".
Price Target | $8.90 |
Price Target Difference | 402.83% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |